BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20801221)

  • 1. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
    Kapadia R; Coffey MC
    Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reovirus - possible therapy of cancer.
    Figova K; Hrabeta J; Eckschlager T
    Neoplasma; 2006; 53(6):457-62. PubMed ID: 17167712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of mammalian reoviruses for use as oncolytic agents.
    Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC
    Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
    Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
    Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus combinations and chemotherapy for the treatment of human cancers.
    Kumar S; Gao L; Yeagy B; Reid T
    Curr Opin Mol Ther; 2008 Aug; 10(4):371-9. PubMed ID: 18683102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic virus therapy for prostate cancer.
    Fukuhara H; Homma Y; Todo T
    Int J Urol; 2010 Jan; 17(1):20-30. PubMed ID: 19832925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Lee CY; Rennie PS; Jia WW
    Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A strategy for genetic modification of the spike-encoding segment of human reovirus T3D for reovirus targeting.
    van den Wollenberg DJ; van den Hengel SK; Dautzenberg IJ; Cramer SJ; Kranenburg O; Hoeben RC
    Gene Ther; 2008 Dec; 15(24):1567-78. PubMed ID: 18650851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
    Mohamed A; Smiley JR; Shmulevitz M
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reovirus: viral therapy for cancer 'as nature intended'.
    Comins C; Heinemann L; Harrington K; Melcher A; De Bono J; Pandha H
    Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):548-54. PubMed ID: 18583112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic vaccinia virus: from bedside to benchtop and back.
    Thorne SH
    Curr Opin Mol Ther; 2008 Aug; 10(4):387-92. PubMed ID: 18683104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reovirus-based therapy for cancer.
    Kelly K; Nawrocki S; Mita A; Coffey M; Giles FJ; Mita M
    Expert Opin Biol Ther; 2009 Jul; 9(7):817-30. PubMed ID: 19527106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
    Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
    Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-selective replication of an oncolytic adenovirus carrying oct-3/4 response elements in murine metastatic bladder cancer models.
    Wu CL; Shieh GS; Chang CC; Yo YT; Su CH; Chang MY; Huang YH; Wu P; Shiau AL
    Clin Cancer Res; 2008 Feb; 14(4):1228-38. PubMed ID: 18281558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
    Black AJ; Morris DG
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic viral therapy using reovirus.
    Thirukkumaran C; Morris DG
    Methods Mol Biol; 2009; 542():607-34. PubMed ID: 19565924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of Genetically RGD σ1-Modified Oncolytic Reovirus That Enhances JAM-A-Independent Infection of Tumor Cells.
    Kawagishi T; Kanai Y; Nouda R; Fukui I; Nurdin JA; Matsuura Y; Kobayashi T
    J Virol; 2020 Nov; 94(23):. PubMed ID: 32907973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.